PRODUCT DEVELOPMENT OF A MEMBRANE TETRASPANIN VACCINE AGAINST SCHISTOSOMIASIS

血吸虫病膜四跨膜疫苗的产品开发

• 批准号: 8186912
• 负责人: Jeffrey Michael Bethony
• 金额: $ 56.18万
• 依托单位: ALBERT B. SABIN VACCINE INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2013-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8186912
• 关键词: Adjuvant; Affect; Africa; Aftercare; Alhydrogel; Animals; Antibodies; Antigens; Area; Binding; Biochemical; Brazil; Caribbean region; Cessation of life; Characteristics; Chronic; Circular Dichroism; Clinic; Clinical; Contractor; Country; DNA Vaccines; Data; Developing Countries; Development; Disease; District of Columbia; Dose; Drug Formulations; Drug resistance; Ensure; Excipients; Family; Fermentation; Fluorescence; Foundations; Funding; Generations; Goals; Head; Human; Immunity; Immunology procedure; Individual; Infection; Institutes; International; Intestinal Schistosomiases; Investigational New Drug Application; Italy; Laboratory Animals; Lead; Life; Link; Low income; Malaria; Manufacturer Name; Maryland; Measures; Membrane; Methodology; Molecular; Morbidity - disease rate; Nature; North Carolina; Oral Poliovirus Vaccine; Outcome; Parasites; Parasitic infection; Pharmaceutical Preparations; Pichia; Praziquantel; Preclinical Testing; Principal Investigator; Process; Program Development; Program Reviews; Proteins; Proteomics; Public Sector; Publishing; Quality Control; Recombinant Proteins; Recombinant Vaccines; Recombinants; Reproducibility; Research Contracts; Resistance; Risk; Risk Management; Schistosoma; Schistosoma mansoni; Schistosomiasis; Serum; Staging; Surface; Surface Antigens; Technology; Technology Transfer; Testing; Thrombospondin 1; Time; Toxicology; Tropical Disease; Tuberculosis; Tuberculosis Vaccines; United States; United States Food and Drug Administration; United States National Institutes of Health; Vaccine Research; Vaccines; Whole Organism; Work; Yeasts; aluminum phosphate; aluminum sulfate; assay development; authority; base; burden of illness; chemotherapy; combat; cost; disability; efficacy testing; experience; expression vector; extracellular; frontier; human PHEMX protein; human subject; innovation; innovative technologies; light scattering; manufacturing process; meetings; neglect; novel; novel strategies; potency testing; prevent; product development; programs; public-private partnership; research clinical testing; response; scale up; stability testing; success; thrombospondin 2; thrombospondin 3; tool; vaccine candidate; vaccine development; vaccine evaluation

项目成果

SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice.

• DOI: 10.1101/2020.11.04.367359
• 发表时间: 2021-02-09
• 期刊: bioRxiv : the preprint server for biology
• 作者: Pollet, Jeroen;Chen, Wen-Hsiang;Bottazzi, Maria Elena
• 通讯作者: Bottazzi, Maria Elena